Here are the DEF 14A proxy statements from OPGEN INC (OPGN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow OPGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OPGN filings page.
OpGen, Inc. is asking stockholders to vote at its virtual 2025 Annual Meeting on February 23, 2026. The agenda includes electing five directors, approving a new 2026 Equity Incentive Plan, and several key capital and governance items.
Stockholders are asked to approve the issuance of up to 889,274 shares of common stock upon exercise of warrants issued in a May 4, 2023 best‑efforts public offering, and to ratify the prior sale and issuance of 7,200,000 shares of common stock to AEI Capital Ltd. for purposes of Rule 16b‑3(d)(2). The Board also seeks approval to change the company name from “OpGen, Inc.” to “CapForce Inc.”, hold an advisory “say on pay” vote on executive compensation, and ratify Beckles & Co., Inc. as independent auditor for 2025.
As of the record date, there were 10,149,411 shares of common stock and 250 shares of Series D Convertible Preferred Stock outstanding, with each preferred share carrying 244.4 votes on an as‑converted basis. AEI Capital Ltd. beneficially owns 7,724,728 shares of common stock, or 75.65%, making the company a controlled company under Nasdaq rules.